Ten-year survival of children with acute lymphoblastic leukemia: A report from the Children's Oncology Group

References

• Miller D R, Leikin S, Albo V, Sather H, Karon M, Hammond D. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. A report from Children's Cancer Study Group. Cancer 1983; 51: 1041–1049
   Google Scholar
• Miller D R, Leikin S, Albo V, Vitale L, Sather H, Coccia P, et al. Use of prognostic factors in improving the design and efficiency of clinical trials in childhood leukemia: Children's Cancer Study Group Report. Cancer Treatment Rep 1980; 64: 381–392
   PubMedGoogle Scholar
• Gaynon P S, Bleyer W A, Steinherz P G, Finklestein J Z, Littman P S, Miller D R, et al. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features: a report of Children's Cancer Study Group Study CCG-193p. Am J Pediatr Hematol Oncol 1988; 10: 42–50
   PubMedGoogle Scholar
• Nachman J, Sather H N, Cherlow J M, Sensel M G, Gaynon P S, Lukens J N, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. J Clin Oncol 1998; 16: 920–930
   PubMed Web of Science ®Google Scholar
• Nachman J B, Sather H N, Sensel M G, Trigg M E, Cherlow J M, Lukens J N, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998; 338: 1663–1671
   PubMed Web of Science ®Google Scholar
• Steinherz P G, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. Cancer 1993; 72: 3120–3130
   Google Scholar
• Tubergen D G, Gilchrist G S, O'Brien R T, Coccia P F, Sather H N, Waskerwitz M J, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features. J Clin Oncol 1993; 11: 527–537
   PubMed Web of Science ®Google Scholar
• Uckun F M, Reaman G, Steinherz P G, Arthur D C, Sather H, Trigg M, et al. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. Leuk Lymphoma 1996; 24: 57–70
   PubMed Web of Science ®Google Scholar
• Abromowitch M, Ochs J, Pui C H, Kalwinsky D, Rivera G K, Fairclough D, et al. High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude total therapy study X. Med Pediatr Oncol 1988; 16: 297–303
   PubMedGoogle Scholar
• Bloomfield C D, Secker Walker L M, Goldman A I, Van Den Berghe H, de la Chapelle A, Ruutu T, et al. Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genet Cytogenet 1989; 40: 171–185
   PubMed Web of Science ®Google Scholar
• Clavell L A, Gelber R D, Cohen H J, Hitchcock-Bryan S, Cassady J R, Tarbell N J, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986; 315: 657–663
   PubMed Web of Science ®Google Scholar
• Freeman A I, Boyett J M, Glicksman A S, Brecher M L, Leventhal B G, Sinks L F, et al. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up. Med Pediatr Oncol 1997; 28: 98–107
   PubMedGoogle Scholar
• Janka G E, Winkler K, Juergens H, Goebel U. Early intensification therapy in high-risk childhood acute lymphocytic leukemia: lack of benefit from high-dose methotrexate. Haematol Blood Transfus 1987; 30: 456–460
   PubMedGoogle Scholar
• Mastrangelo R, Poplack D, Bleyer A, Riccardi R, Sather H, D'Angio G. Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment. Med Pediatr Oncol 1986; 14: 191–194
   PubMedGoogle Scholar
• Pui C H, Frankel L S, Carroll A J, Raimondi S C, Shuster J J, Head D R, et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. Blood 1991; 77: 440–447
   PubMed Web of Science ®Google Scholar
• Riehm H, Feickert H J, Schrappe M, Henze G, Schellong G. Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. Haematol Blood Transfus 1987; 30: 139–146
   PubMedGoogle Scholar
• Schorin M A, Blattner S, Gelber R D, Tarbell N J, Donnelly M, Dalton V, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 1994; 12: 740–747
   PubMed Web of Science ®Google Scholar
• Smith M, Arthur D, Camitta B, Carroll A J, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18–24
   PubMed Web of Science ®Google Scholar
• Gaynon P S, Steinherz P G, Bleyer W A, Ablin A R, Albo V C, Finklestein J Z, et al. Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Children's Cancer Study Group. Lancet 1988; 2: 921–924
   PubMed Web of Science ®Google Scholar
• Gaynon P S, Steinherz P G, Bleyer W A, Ablin A R, Albo V C, Finklestein J Z, et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Children's Cancer Group Study CCG-106. J Clin Oncol 1993; 11: 2234–2242
   PubMed Web of Science ®Google Scholar
• Steinherz P G, Gaynon P S, Breneman J C, Cherlow J M, Grossman N J, Kersey J H, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia – the importance of early marrow response: report from the Children's Cancer Group. J Clin Oncol 1996; 14: 389–398
   PubMed Web of Science ®Google Scholar
• Steinherz P G, Gaynon P S, Breneman J C, Cherlow J M, Grossman N J, Kersey J H, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer 1998; 82: 600–612
   PubMed Web of Science ®Google Scholar
• Tubergen D G, Gilchrist G S, O'Brien R T, Coccia P F, Sather H N, Waskerwitz M J, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Children's Cancer Group report. J Clin Oncol 1993; 11: 520–526
   PubMed Web of Science ®Google Scholar
• Bleyer W A, Coccia P F, Sather H N, Level C, Lukens J, Niebrugge D J, et al. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol 1983; 1: 317–325
   PubMed Web of Science ®Google Scholar
• Lange B J, Blatt J, Sather H N, Meadows A T. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Children's Cancer Group study. Med Pediatr Oncol 1996; 27: 15–20
   PubMedGoogle Scholar
• Steinherz P G, Gaynon P S, Miller D R, Reaman G, Bleyer A, Finklestein J, et al. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen – a new intensive therapy protocol: a report from the Children's Cancer Study Group. J Clin Oncol 1986; 4: 744–752
   PubMed Web of Science ®Google Scholar
• Anderson J R, Wilson J F, Jenkin D T, Meadows A T, Kersey J, Chilcote R R, et al. Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 1983; 308: 559–565
   PubMed Web of Science ®Google Scholar
• Reaman G H, Sposto R, Sensel M G, Lange B J, Feusner J H, Heerema N A, et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 1999; 17: 445–455
   PubMed Web of Science ®Google Scholar
• Coccia P, Bleyer W, Siegel S, Lukens J N, Gross S, Miller D R, . Development and preliminary findings of Children's Cancer Study Group protocols (161, 162 and 163) for low-, average- and high-risk acute lymphoblastic leukemia in children. S Murphy, J Gilbert, et al. Elsevier Science Publishing Co, Inc, Amsterdam 1983; 241–250, Leukemia Research: Advances in Cell Biology and Treatment
   Google Scholar
• Uckun F M, Muraguchi A, Ledbetter J A, Kishimoto T, O'Brien R T, Roloff J S, et al. Biphenotypic leukemic lymphocyte precursors in CD2 + CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. Blood 1989; 73: 1000–1015
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Peto R, Pike M C, Armitage P, Breslow N E, Cox D R, Howard S V, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II. Analysis and examples. Br J Cancer 1977; 35: 1–39
   PubMed Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170
   PubMedGoogle Scholar
• Cox D R. Regression models and life tables. J R Stat Soc B 1972; 34: 187–220
   Google Scholar
• Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig W-D, henze G, et al. Long-term results of four consecutive trials in childhood ALL performred by the ALL-BFM study group from 1981 to 1995. Leukemia 2000; 14: 2205–2222
   PubMed Web of Science ®Google Scholar
• Gaynon P S, Trigg M E, Heerema N A, Sensel M G, Sather H N, Hammond G D, Bleyer W A. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1883–1995. Leukemia 2000; 14: 2223–2233
   PubMed Web of Science ®Google Scholar
• Silverman L B, Declerck L, Gelber R D, Kimball Dalton V, Asselin B L, Barr R D, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981–1995). Leukemia 2000; 14: 2247–2256
   PubMed Web of Science ®Google Scholar
• Pui C-H, Boyett J M, Rivera G K, Hancock M L, Sandlund J T, Ribeiro R C, et al. Long-term results of total therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000; 14: 2286–2294
   PubMed Web of Science ®Google Scholar
• Eden O B, Harrison G, Richards S, Lilleyman J S, Bailey C C, Chessells J M, et al. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980–1997. Leukemia 2000; 14: 2307–2320
   PubMed Web of Science ®Google Scholar
• Gaynon P S, Desai A A, Bostrom B C, Hutchinson R J, Lange B J, Nachman J B, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997; 80: 1717–1726
   PubMed Web of Science ®Google Scholar
• Rivera G K, Pinkel D, Simone J V, Hancock M L, Crist W M. Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med 1993; 329: 1289–1295
   PubMed Web of Science ®Google Scholar
• Chessells J M. Childhood acute lymphoblastic leukemia: the late effects of treatment. Br J Haematol 1983; 63: 369–378
   Google Scholar
• Gaynon P S, Steinherz P G, Reaman G H, Bleyer W A, Sather H, Hammond G D. Strategies for the treatment of children with acute lymphoblastic leukemia and unfavorable presenting features. Haematol Blood Transfus 1987; 30: 167–172
   PubMedGoogle Scholar
• Bostrom B C, Sensel M R, Sather H N, Gaynon P S, La M K, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003; 101: 3809–3817
   PubMed Web of Science ®Google Scholar
• Schrappe M, Reiter A, Ludwig W D, Harbott J, Zimmermann M, Hiddemann W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90: German–Austrian–Swiss ALL-BFM Study Group. Blood 2000; 95: 3310–3322
   PubMed Web of Science ®Google Scholar
• Camitta B, Mahoney D, Leventhal B, Lauer S J, Shuster J J, Adair S, et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1994; 12: 1383–1389
   PubMed Web of Science ®Google Scholar